Dr. John B. Etheridge, MD
Pediatrics (Pediatrics Physician)
1320 Ribaut Rd
Port Royal, SC 29935
Who else practices at this address →
Beaufort County is a federal primary care shortage area; it also includes dental (41% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
SC license 19936
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $4.35 in total to this clinician.
| Pfizer Inc. | $4.35 |
|---|
| Food and Beverage | $4.35 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $45,480 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized placebocontrolled observerblinded trial to evaluate the safety of a 6VALENT ospabased lyme disease vaccine VLA15 in healthy children 5 through 17 years of age
Pfizer Inc. - A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT04649151 - Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
Sanofi Pasteur Inc. · Completed · NCT05513053
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.